Artificial intelligence is transforming biology in powerful ways, but the same tools that help design life-saving drugs can also help create bioweapons. The U.S. government now faces an urgent challenge: secure and organize biological data in ways that fuel innovation while preventing misuse by hostile actors or rogue scientists.

Why Is Biological Data Suddenly So Critical to AI Risk?

For decades, bioweapons were a concern primarily for biosecurity experts and military planners. But artificial intelligence has fundamentally changed the threat landscape. AI tools can now generate whole-genome sequences, design novel proteins, predict how genetic changes will behave, and optimize synthetic biology experiments entirely in software, without ever touching a lab. These capabilities compress what once took years of research into weeks or days.

The problem is stark: while competitors like China are building coordinated, integrated AI-biology ecosystems, the U.S. biological data environment remains fragmented, underfunded, and insecure. This fragmentation isn't just inefficient; it's a security vulnerability. Without standardized, well-curated datasets, the U.S. cannot fully leverage AI to defend against biological threats, nor can it easily prevent bad actors from accessing the raw materials they need to cause harm.

What Could Go Wrong With AI and Biology?

The risks fall into two categories: translational risks and existential risks. Translational risks occur when AI models trained on incomplete or poorly curated data produce incorrect findings. A researcher might waste months pursuing a biotech application that doesn't actually work in the real world. This is especially dangerous in areas like early warning systems for pandemics or rapid development of medical countermeasures to biological weapons.

The existential risk is more alarming: nefarious actors could misuse AI tools to create enhanced bioweapons and make them more accessible to a wider range of actors. The Biological Weapons Convention, signed in 1975, has never had a verification protocol. AI changes that calculus entirely. An individual or small group with computational resources and access to biological data could theoretically engineer threat agents that were previously beyond their reach.

How Can the U.S. Protect Itself While Advancing Biology?

• Data Curation and Standardization: The U.S. government must invest in generating, storing, and carefully disseminating AI-ready biological datasets that are both secure and standardized. This allows researchers to train AI models on reliable information while keeping sensitive data out of the wrong hands.
• Integrated National Strategy: Rather than allowing biotech development to proceed in fragmented silos, policymakers need a concrete national approach that coordinates data generation across government agencies, academic institutions, and private companies.
• Dual-Use Monitoring: Companies like OpenAI are already establishing programs, such as the Rosalind Biodefense Program, to both understand misuse risks and leverage AI tools to advance therapeutics and pandemic preparedness. This model of internal oversight should become standard practice.

The fiscal year 2026 National Defense Authorization Act included specific measures on generating biological data to advance artificial intelligence and protecting U.S. biological data from theft or misuse. But policy is moving slower than technology. The pace of positive developments in AI-driven biology is both inspiring the policy community and complicating how quickly regulations can adapt.

What Are the Real-World Benefits of AI in Biology?

It's important to note that AI in biology isn't all risk. The same tools that pose security challenges are already delivering remarkable benefits. AI models like AlphaFold can predict a protein's structure and how it interacts with other molecules, accelerating drug discovery. Tools like BoltzGen can design novel protein binders for therapeutic use. ART allows researchers to predict and optimize synthetic biology experiments in software before running them in the lab.

These applications enable personalized medicine, precision agriculture, and dramatically faster discovery and manufacturing cycles. The bioeconomy could boom if the U.S. can harness AI's potential while managing its risks. But that requires solving the data problem first.

"While competitors are building coordinated AI-bio ecosystems, the U.S. biodata environment remains fragmented, underfunded, and insecure," noted experts in early 2026.

Harshini Mukundan, Crystal Grant, and Christine Parthemore, Council on Strategic Risks

Why Is This a Moment of Urgency?

Biological complexity is both a challenge and an opportunity. The same biological process can be studied through different model systems, using different biochemical measurements like genomics, proteomics, and transcriptomics, at different time points, with different instruments and analytical methods. This heterogeneity makes it extremely difficult to integrate data into larger, AI-ready datasets. Yet that integration is precisely what's needed to train powerful AI models that can accelerate both beneficial and defensive applications.

The goal of making bioweapons obsolete as a mass-destruction threat can now only be realized through efforts to understand and address AI-driven technology in this landscape. This is not a problem that will solve itself. It requires deliberate policy action, sustained investment, and coordination across government, academia, and industry. The window to act is narrowing as AI capabilities advance and the dual-use risks become more pronounced.